Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

Mostrar otras versiones (1)

BACKGROUND: This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with advanced gastric cancer, and the novel oral antiangiogenic agent TSU-68 could contribute to gastric cancer treatment. METHODS: Ninety-three patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798959/
https://www.ncbi.nlm.nih.gov/pubmed/24045669
http://dx.doi.org/10.1038/bjc.2013.555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798959/
https://www.ncbi.nlm.nih.gov/pubmed/24045669
http://dx.doi.org/10.1038/bjc.2013.555

Ejemplares similares